IKT
Inhibikase Therapeutics, Inc.
$2.07
+0.02 (+0.98%)
At close · Jul 8
Market Cap
$270.01M
Shares
132,032,636
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2024
Net Income
-$48.26M
-75.4%
FY2025
Operating Margin
-7711.98%
+6974.2pp
FY2023
Diluted EPS
-$0.49
+57.8%
FY2025
Operating Cash Flow
-$27.79M
-45.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| — | — | $0 | $260.5K | $123.44K | $3.1M | |
| $4.26M | $3.72M | $1.07M | $1.06M | $74.45K | — | |
| $30.12M | $29.79M | $17.21M | $13.62M | $12.03M | $11.36M | |
| $25.68M | $23.56M | $11.38M | $6.73M | $6.22M | $6.51M | |
| $55.22M | $51.97M | $28.59M | $20.35M | $18.25M | $17.87M | |
| -$55.22M | -$51.97M | -$28.59M | -$20.09M | -$18.13M | -$14.77M | |
| — | — | — | -7711.98% | -14686.17% | -476.23% | |
| — | — | — | — | — | $19.92K | |
| — | -$48.26K | — | — | — | — | |
| $0 | $0 | — | — | — | — | |
| -$50.96M | -$48.26M | -$27.52M | -$19.03M | -$18.05M | -$14.79M | |
| — | — | — | -7304.73% | -14625.85% | -476.88% | |
| USD/shares | — | -$0.49 | -$1.16 | -$3.57 | -$4.32 | — |
| USD/shares | — | -$0.49 | -$1.16 | -$3.57 | -$4.32 | — |
| shares | — | 98.31M | 23.71M | 5.33M | 4.2M | 3.03M |
| shares | — | 98.31M | 23.71M | 5.33M | 4.2M | 3.03M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.